Abstract #0370
Direct imaging of gemcitabine delivery in pancreatic ductal adenocarcinoma (PDAC) using CEST MRI
Yuguo Li 1,2 , Kannie W.Y. Chan 1,2 , Theodore Ewachiw 3 , Michael T McMahon 1,2 , Peter C.M. Van Zijl 1,2 , Zeshaan Rasheed 3 , and Guanshu Liu 1,2
1
F.M. Kirby Research Center for Functional
Brain Imaging, Kennedy Krieger Institute, Baltimore, MD,
United States,
2
Department
of Radiology, Johns Hopkins University, Baltimore, MD,
United States,
3
Department
of Oncology, Johns Hopkins University, Baltimore, MD,
United States
One formidable challenge in treating advanced pancreatic
ductal adenocarcinoma (PDAC) is the highly heterogeneous
vascular barriers that hinder efficacious drug delivery.
Here, we propose a new approach to monitor delivery
directly using the inherent Chemical Exchange Saturation
Transfer (CEST) MRI signal carried by the drug. Our
results first showed that gemcitabine, the first-line
treatment for PDAC, could be readily detected by CEST
MRI via its exchangeable amino (2.3 ppm) and hydroxyl
(1.0 ppm) protons. We conclude that direct CEST MR
imaging of the uptake and distribution of gemcitabine in
PDAC tumors can be accomplished without the use of
additional imaging agents.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
